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Abstract
OBJECTIVES: The aim of the present study was to evaluate the diagnostic accuracy of matrix metalloproteinase-9 and tissue inhibitor of
metalloproteinase-1 in differentiating benign from malignant exudative pleural effusions.
METHODS: This is a unicentre observational study including 97 consecutive patients with exudative pleural effusions. Metalloproteinase-9,
tissue inhibitor of metalloproteinase-1, lactate dehydrogenase, ferritin, carcinoembryonic antigen and carbohydrate antigen 15-3 were
measured in pleural effusion and serum by enzyme-linked immunosorbent assay. The activity of metalloproteinase-9 was also evaluated
by substrate zymography. The data were correlated with final diagnosis of pleural effusions to evaluate the diagnostic accuracy.
RESULTS: Of the 97 eligible patients, 6 were excluded. Of the 91 patients included in the study, 70 had malignant pleural effusions and
21 had benign pleural effusions. Both in sera and pleural effusions, matrix metalloproteinase-9 (P < 0.0001), tissue inhibitor of metallo-
proteinase-1 (P < 0.0001) and carcinoembryonic antigen (P < 0.0001) levels were higher in neoplastic patients than in benign group.
Zymography analysis showed a most prominent band at a molecular weight of 92 kDa (metalloproteinase-9) whereas a less intense
band was observed at 72 kDa (metalloproteinase-2). A significant correlation was found between metalloproteinase-9 and tissue in-
hibitor of metalloproteinase-1 levels in pleural effusion (P < 0.0001; r = 0.8) and serum (P < 0.03; r = 0.2). Pleural effusion metalloprotei-
nase-9 and tissue inhibitor of metalloproteinase-1 levels showed higher value of sensitivity (97 and 91%, respectively) and specificity
(90 and 95%, respectively) compared with other standard markers. Serum metalloproteinase-9 and tissue inhibitor of metalloprotei-
nase-1 levels showed similar results. Among 70 neoplastic patients, 29 had negative pleural cytology. Of these, 25 presented elevated
levels of metalloproteinase-9 and tissue inhibitor of metalloproteinase-1, whereas 4 patients had elevated levels of one of the two
markers.
CONCLUSIONS: Our results showed that metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 might be valuable markers in
differentiating benign from malignant pleural effusions. Their levels are neither influenced by the histology and tumour origin nor by
the presence of tumour cells in pleural effusions. Thus, their use in clinical practice could help in the selection of patients needing
more invasive procedures, such as thoracoscopic biopsy.
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INTRODUCTION
Differential diagnosis of exudative pleural effusions (PEs) still remains
a diagnostic problem. The diagnostic accuracy of cytological exam-
ination of PEs is about 60% and computed tomography-guided
biopsy adds 7–13% of positive findings [1]. Video-assisted thoracic
surgery (VATS) remains the gold standard procedure in the diagnosis
of exudative PEs, which allows to perform biopsies in pathological
pleural areas. However, VATS is a surgical procedure that may be
contra-indicated in unfit patients.
In the last years, several new markers have been evaluated to
increase the diagnostic accuracy of cytological examination of
exudative PEs with controversial results [1, 2]. The exudative PEs, in
fact, may have different pathogenesis related to the underlying
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diseases. Thus, it is unlikely that a single mediator plays a key role
in all types of exudative PEs.
The matrix metalloproteinases (MMPs) are a family of pro-
teases capable of degrading all components of the extracellular
matrix. Their activity is prevalently controlled by the tissue-
specific inhibitors of metalloproteinases (TIMPs). The alteration
of the balance between MMPs and their TIMPs has been sug-
gested to play a role in the pathogenesis of benign and malig-
nant PEs.
In humans, the MMP family is composed of at least 21 differ-
ent members. Among these, metalloproteinase-9 (MMP-9) is
one of the most powerful factors involved in angiogenesis and
in degradation of the basement membrane. MMP-9 secretion is
of particular interest in pleural diseases, since this gelatinase, by
degrading Type IV collagen, contributes to loss of integrity of
the basement membrane around blood vessels and under the
mesothelial layer, leading to fluid accumulation in the pleural
space [2–4].
The aim of the present study was to evaluate whether MMP-9
and its specific inhibitor TIMP-1 might have a role in the differen-
tial diagnosis of exudative PEs, in order to select which patients
will benefit of invasive procedures such as VATS biopsy.
MATERIALS ANDMETHODS
Study design
This was a unicentre observational study. All consecutive patients
with exudative PEs presented to our unit in the last two years (April
2013–May 2015) were eligible. Patients were excluded if (i) they
refused invasive procedure; (ii) they did not have a definitive diag-
nosis at completion of diagnostic work-up; (iii) they received
immune-stimulating agent, anti-cancer treatment, anti-tuberculosis
treatment, corticosteroid or other non-steroid anti-inflammatory
drug treatment; or (iv) serum and PE samples were spoiled for de-
termination of markers.
MMP-9, TIMP-1, lactate dehydrogenase (LDH), ferritin, carci-
noembryonic antigen (CEA) and carbohydrate antigen 15-3 (CA
15-3) were measured in PE and in serum by enzyme-linked im-
munosorbent assay (ELISA). In addition, the activity of MMP-9 was
also evaluated by substrate zymography.
PEs were split into two groups depending on diagnosis (PEs of
benign origin versus PEs of malignant origin) and the intergroup
difference of PE markers and serum markers was statistically ana-
lysed. The readers of the index tests were blind to the results of
the other tests.
The protocol of this study was approved by the Hospital Ethics
Committee of the Second University of Naples and written
informed consent was obtained from all cases before being
included in the study.
Patients
Ninety-seven consecutive patients with exudative PEs were eli-
gible. All samples were designed as exudate according to the Light
criteria [5]. The presence of malignant cells in the pleural fluid or
in pleural biopsy indicated the malignant origin of PEs. Benign
pleural effusion was defined of parapneumonic origin when asso-
ciated with bacterial pneumonia, including empyema; of
tubercular origin when mycobacterium tuberculosis was found in
pleural fluid, sputum, bronchial lavage fluid or pleural biopsy spe-
cimen (positive smear or culture); or revealed granuloma and
other granulomatous diseases.
Sample processing
PEs were collected via diagnostic thoracentesis, collected in sterile
tube without anticoagulant and rapidly brought to our laboratory
with a blood sample of the same patients. Pleural fluids and blood
samples were immediately centrifuged at 1500 rpm for 7 min at
4°C and supernatants were aliquoted and stored at −70°C awaiting
analysis of MMP-9 TIMP-1, LDH, ferritin and CA 15-3. Each
aliquot was used only one in order to prevent enzyme activation
due to freeze-thawing processes.
Markers measurements
The levels of MMP-9 (ng/ml), TIMP-1 (pg/ml), LDH (UI/l), ferritin
(ng/ml), CEA (ng/ml) and CA 15-3 (kU/l) were determined within
PE and serum using a ‘sandwich’ ELISA kit (R&D Systems, Inc.,
Minneapolis, MN, USA) according to the manufacturer’s guidelines.
Zymography
Gelatinases A and B were purchased from Hoffmann-La Roche Ltd
(Basel, Switzerland). Triton X-100, Calcium chloride (CaCl2), gly-
cerol, gelatin, ethylene-diaminetetraacetic (EDTA) phenylmethylsul-
phonyl fluoride (PMSF) were from Sigma Chemical Co. (St Louis, MO,
USA). The protein assay reagent was from Bio-Rad Laboratories. All
other reagents were available from commercial sources.
Gelatin Zymography: MMP activity was determined through
zymographic analysis under denaturating but non-reducing
conditions as previously described. Total serum proteins (25 µg)
or pleural effusion proteins (15 µg) were mixed with sample
buffer and applied directly without heating or reduction to 7.5%
(w/v) acrylamide gels containing 0.1% (w/v) of gelatin. After the
removal of SDS from gel by incubation in 2.5% (v/v) Triton
X-100 for 1 h, the gels were incubated at 37°C for 18 h in 50
mM Tris-HCl pH 7.6 containing 0.2 M NaCl, 5 mM CaCl2 and
0.02% (w/v) Brij 35. Gels were stained for 1 h in 30% methanol,
10% glacial acetic acid containing 0.5% (w/v) Coomassie Brilliant
Blue G 250 and destained in the same solution without dye for
several hours. The gelatinolytic activity of each collagenase was
evident as a clear band against the blue background of stained
gelatin. The molecular size of bands displaying enzymatic activ-
ity was identified in comparison with prestained standard
protein, as well as with purified gelatinase A or gelatinase B. To
normalize the possible difference between zymograms, an in-
ternal serum or pleural effusion sample from a patient was
incorporated in every gel.
Control gels for MMPs. Control gels contained either of the
MMP selective inhibitors, 20 mM EDTA or 10 mM 1,10 phenan-
throline, in the MMP incubation buffer to confirm that lysis
bands were the results of MMPs. Furthermore, the character of
proteolytic bands was analysed by incubating the identical
zymograms in 0.1 mg/ml of PMSF, a serine protease inhibitor;
or 2 mM Pefabloc, an irreversible serine protease inhibitor
(data not shown).
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Analysis of the gels. Following zymography, the degree of gelatin
digestion was quantified as previously described. Briefly, we used an
image analysis software (ImageQuant TL, Amersham Bioscience,
Chicago, IL, USA) according to the manufacturer’s specifications. The
image of the gel was inverted to reveal dark bands on a white back-
ground. The molecular weight, volume and background of each
band were determined. The relative amounts of the different forms
of both serum and pleural effusion gelatinases were expressed as
the integrated density × 10−3 (volume) of all the pixels above the
background of each band.
Statistical analysis
Data are presented as median and interquartile range (IRQ).
Comparisons between different groups were performed using
Mann–Whitney U-tests. In neoplastic patients, analysis of variance
(ANOVA) test was used to compare the different origins of PEs.
The correlation between MMP-9 and TIMP-1 levels was assessed
with Spearman’s rank correlation test. The accuracy of variables to
distinguish malignant from benign PEs was calculated with re-
ceiver operating characteristics (ROC) curve. For the optimum
cut-off point provided by ROC analysis, sensitivity, specificity,
positive predictive value (PPV) and negative predictive value
(NPV) were calculated. A value of P < 0.05 was considered statistic-
ally significant. MedCalc® statistical software was used for analysis.
RESULTS
Of the 97 eligible patients, 6 were excluded due to the lack of de-
finitive diagnosis (n = 1) and spoiled samples (n = 5). Thus, our
study population included 91 patients [65 male and 26 female,
median age 64 (51–75)]; 21 patients with benign PEs (10 para-
pneumonic, 6 empyema, 5 tuberculosis) and 70 with PEs of malig-
nant origin due to lung (n = 27; 38.5%), gastrointestinal (n = 20;
28.5%) and breast (n = 5; 7%) cancers and mesotheliomas (n = 18;
26%). The flow chart of study population is reported in Fig. 1.
All malignant patients underwent VATS which detected multiple
pleural metastases. Of these, 41/70 (58%) patients also presented a
positive fluid cytology for malignant cells. All patients with
empyema and 9/10 (90%) patients with PEs of parapneumonic
origin presented a macroscopic pus whereas only 1/10 (10%)
patient presented clinical and radiological signs consistent with
pneumonia and non-purulent pleural fluid. Tube thoracostomy
and drainage were performed in 15 patients (9 with parapnuemo-
nic PEs and 6 with empyema). Five patients with empyema
required pleural decortication performed via VATS (n = 4) and
thoracotomy (n = 1). In patients with no purulent fluid parapneu-
monic PEs, thoracentesis and medical therapy were performed.
Among patients with tuberculosis PEs, 2/5 (40%) had positive
pleural fluid culture, 2/5 (40%) presented positive sputum culture
and 1/5 (20%) had a granuloma on pleural biopsy which shows
staining for the acid-fast bacilli. In all cases, PEs resolved with chest
drainage and specific medical therapy.
Marker levels in pleural effusion
The results are reported in Table 1 and Fig. 2. Neoplastic patients
compared with control group had higher levels of MMP-9
(P < 0.0001, Fig. 2A), TIMP-1 (P < 0.0001, Fig. 2B) and CEA
(P < 0.0001; Fig. 2C) while no significant difference was found regard-
ing LDH (P = 0.7), ferritin (P = 0.2) and CA 15-3 (P = 0.2) levels.
Among neoplastic patients, lung cancer, extrathoracic cancer and
mesothelioma showed similar value of MMP-9 levels (1927 ± 163
vs 2121 ± 266 vs 1949 ± 568; P = 0.08) and of TIMP-1 levels
(1811 ± 529 vs 2100 ± 382 vs 2008 ± 458; P = 0.1).
Marker levels in serum
The results are reported in Table 1 and Fig. 2. Neoplastic patients
compared with benign patients had higher levels of MMP-9
(P < 0.0001; Fig. 2D), TIMP-1 (P < 0.0001; Fig. 2E) and CEA
(P < 0.0001; Fig. 2F) while no significant difference was found
regarding LDH (P = 0.1), ferritin (P = 0.6) and CA 15-3 (P = 0.7) levels.
Figure 1: Flow chart of study population.
Table 1: Markers levels in pleural effusion and serum
Variable Malignant Benign P-value
Pleural effusion
MMP-9 (ng/ml) 2036 (1965–2177) 587 (533–647) <0.0001
TIMP-1 (pg/ml) 2095 (1955–2204) 646 (582–706) <0.0001
CEA (ng/ml) 1.7 (1.4–1.8) 1.1 (1.0–1.2) <0.0001
LDH (UI/l) 220 (208–232) 224 (214–236) 0.7
Ferritin (ng/ml) 551 (497–602) 521 (491–565) 0.2
CA 15-3 (kU/l) 50 (45–55) 49 (41–52) 0.7
Serum
MMP-9 (ng/ml) 185 (67–203) 71 (58–76) <0.0001
TIMP-1 (pg/ml) 181 (174–184) 53 (47–83) <0.0001
CEA (ng/ml) 1.2 (0.9–1.3) 0.6 (0.5–0.7) <0.0001
LDH (UI/l) 147 (135–159) 140 (135–149) 0.1
Ferritin (ng/ml) 490 (436–541) 483 (440–517) 0.6
CA 15-3 (kU/l) 41 (36–46) 40 (38–44) 0.7
CEA: carcinoembryonic antigen; TIMP: tissue-specific inhibitors of
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Among neoplastic patients, lung cancer, extrathoracic cancer
and mesothelioma showed similar value of MMP-9 (208 ± 123 vs
185 ± 28 vs 180 ± 52; P = 0.4) and of TIMP-1 (173 ± 54 vs 183 ± 34
vs 175 ± 23; P = 0.7) levels.
In addition, PE MMP-9 (P < 0.0001) and PE TIMP-1 (P < 0.0001)
levels were significantly higher than serum MMP-9 and TIMP-1
levels.
Zymography
In all neoplastic patients but one, multiple bands of gelatinolytic activ-
ity were evident on gelatin zymography of PE and serum. The most
prominent band migrated at a molecular weight of 92 kDa (MMP-9).
A less intense band was often, but not always, seen at 72 kDA [metallo-
proteinase-2 (MMP-2)].
Figure 2: MMP-9 (P < 0.0001, A), TIMP-1 (P < 0.0001, B) and CEA (P < 0.0001; C) in pleural effusions and MMP-9 (P < 0.0001; D), TIMP-1 (P < 0.0001; E) and CEA
(P < 0.0001; F). CEA: carcinoembryonic antigen; TIMP: tissue-specific inhibitors of metalloproteinases 1.
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Only one patient with empyema showed the presence of gelati-
nolytic band at a molecular weight of 72 kDa (MMP-2). A repre-
sentative gel is reported in Fig. 3.
Diagnostic accuracy of pleural effusion markers
The ROC curves of PE markers are reported in Table 2 and Fig. 4A.
PE MMP-9 levels reached a sensitivity of 97% (95% CI: 90.1–99.7),
a specificity of 90% (95% CI: 69.6–99.8); a PPV of 97% (95% CI:
90.1–99.7); and a NPV of 90% (95% CI: 69.5–98.8) when a cut-off
value >845 pg/ml was applied.
PE TIMP-1 levels reached a sensitivity of 91% (95% CI: 82.3–
99.1), a specificity of 95% (95% CI: 76.2–99.9); a PPV of 98% (95%
CI: 91.7–100); and a NPV of 76% (95% CI: 56.2–91) when a cut-off
value >904 pg/ml was applied.
Area under curve (AUC) of PE MMP-9 levels was significantly
higher compared with that of CEA (P = 0.006); of LDH (P < 0.0001),
of ferritin (P < 0.0001); and of CA 15-3 (P < 0.0001).
AUC of PE TIMP-1 levels was significantly higher compared with
that of CEA (P = 0.02); of LDH (P = 0.003), of ferritin (P < 0.0001);
and of CA 15-3 (P < 0.0001).
No significant difference was found between AUC of PE MMP-9
and PE TIMP-1 levels (P = 0.2).
Diagnostic accuracy of serum markers
The ROC curves of serum markers are reported in Table 2 and
Fig. 4B. Serum MMP-9 levels reached a sensitivity of 95% (95% CI:
88–99.1), a specificity of 85% (95%CI: 63.7–97); a PPV of 95% (95%
CI: 88–99.1); and a NPV of 85% (95% CI: 63.6–96.9) when a cut-off
value >86 pg/ml was applied.
Serum TIMP-1 levels reached a sensitivity of 95% (95% CI: 88–
99.1), a specificity of 80% (95% CI: 58.1–94.6); a PPV of 94% (95%
CI: 86.2–98.5); and a NPV of 84% (95% CI: 62–96.8) when a cut-off
value >98 pg/ml was applied.
AUC of serum MMP-9 levels was significantly higher compared
with that of LDH (P = 0.008), of ferritin (P < 0.0001); and of CA 15-3
(P < 0.0001).
AUC of serum TIMP-1 levels was significantly higher compared
with that of LDH (P < 0.0001), of ferritin (P = 0.0003); and of CA
15-3 (P < 0.0001).
Table 2: Characteristics of ROC curve
Variable AUC SE 95% CI
Pleural effusion
MMP-9 0.946 0.0277 0.878–0.983
TIMP-1 0.912 0.0332 0.834–0.961
CEA 0.777 0.0513 0.678–0.858
LDH 0.523 0.0674 0.416–0.629
Ferritin 0.592 0.0664 0.484–0.694
CA 15-3 0.576 0.0675 0.468–0.679
Serum
MMP-9 0.859 0.0628 0.770–0.923
TIMP-1 0.891 0.0523 0.808–0.947
CEA 0.807 0.0503 0.711–0.882
LDH 0.593 0.0630 0.484–0.694
Ferritin 0.537 0.0691 0.430–0.643
CA 15-3 0.521 0.0591 0.414–0.627
CA 15-3: carbohydrate antigen 15-3; CEA: carcinoembryonic antigen;
TIMP: tissue-specific inhibitors of metalloproteinases 1; LDH: lactate
dehydrogenase; ROC: receiver operating characteristics; SE: standard
error of the mean; CI: confidence interval; AUC: area under curve;
MMP-9: metalloproteinase-9.
Figure 3: Typical gelatin zymographs in 4 PEs and serum samples. Lane 1 repre-
sentative empyema; Lane 2 through 4 representative malignant disease. Lane 1
showed a predominant band at 72 kDa (MMP-2). The other lanes contained a
more evident band at 92 kDa (MMP-9) and a less evident band at 72 kDa
(MMP-2). PEs: pleural effusions.
Figure 4: ROC curves of markers in pleural effusion (A) and serum (B). CEA: car-
cinoembryonic antigen; TIMP: tissue-specific inhibitors of metalloproteinases
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No significant difference was found between AUC of serum
MMP-9 levels versus AUC of TIMP-1 levels (P = 0.7); of MMP-9
versus CEA levels (0.4); and of TIMP-1 versus CEA (P = 0.7).
Correlation between MMP-9 and tissue-specific
inhibitors of metalloproteinases-1
A significant correlation was found between PE MMP-9 and PE
TIMP-1 levels (P < 0.0001; r = 0.8; 95% CI: 0.84–0.93; Fig. 5A); and
serum MMP-9 and serum TIMP-1 levels (P < 0.03; r = 0.2; 95% CI:
0.02–0.41; Fig. 5B).
No significant correlation was found between PE MMP-9 and
serum MMP-9 (P = 0.3; r = −0.1; 95% CI: −0.30 to 0.10; Fig. 5C).
Similar results were found for TIMP-1 (P = 0.07; r = −0.2; 95% CI:
−0.39 to 0.112; Fig. 5D).
Pleural effusion tissue-specific inhibitors of
metalloproteinases-1 and MMP-9 and cytological
examination
Among malignant group, fluid cytology was positive for malignant
cells in 41/70 (58%) whereas it was negative in the remaining 29/
70 (42%) cases.
Malignant PEs and no-malignant PEs showed similar MMP-9
levels [2014 (1874–2145) vs 2143 (2014–2151); P = 0.1] and
TIMP-1 [2073 (1933–2204) vs 2197 (2072–2205); P = 0.1].
Among 29 neoplastic patients with negative pleural cytology, 25
had PE MMP-9 and PE TIMP-1 levels above the cut-off levels, and
4 patients had at least one of the two PE marker levels (MMP-9 in
3 cases and TIMP-1 in 1 case) above the cut-off levels.
DISCUSSION
Infection and cancer are the main causes of exudative PEs. The dif-
ferential diagnosis may be sometimes challenging because the
mechanism of PE formation is multifactorial and not completely
understood. The imbalance of MMP and TIMP enzymes favours
the proteolitic processes that alter the integrity of underlying
basement membrane facilitating fluid influx within pleural space
in several diseases including cancer [6]. In the present paper, we
hypothesized that MMP-9 and its specific inhibitor TIMP-1 could
be useful markers in the differential diagnosis of exudative PEs.
We found higher levels of MMP-9 and TIMP-1 in PEs of malig-
nant origin than in PEs of benign origin. These results are in agree-
ment with other reports that found increased levels of MMP-9 in
serum of patient with breast, gastric, colon, prostate and lung
cancers [7–10]. The degradation of the extracellular matrix by
tumour cells is a critical step in tumour metastasis, as the
Figure 5: A significant correlation was found between PE MMP-9 and PE TIMP-1 levels (A) and serum MMP-9 and serum TIMP-1 levels (B). No significant correlation was
found between PE MMP-9 and serumMMP-9 (C). Similar results were found for TIMP-1 (D). PE: pleural effusion; TIMP: tissue-specific inhibitors of metalloproteinases 1.
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basement membrane and interstitial stroma represent the first
barrier to tumour spread. Although several proteolytic enzymes
are involved in this process, MMP-9 plays a critical role, since it
degrades Type IV collagen and contributes to loss of integrity of
the basement membrane around blood vessels and under meso-
thelial layer. The alteration of vascular permeability leads to fluid
accumulation in the pleural space [11].
Conversely, other studies have shown the presence of several
MMPs, including MMP-9, in tuberculosis pleural fluid. Park et al.
[12] found a significant increase in MMP-9 in tuberculosis PEs
compared with transudates and malignant PEs. Similar results
were also reported by Vatansever et al. [13] and by Sheen et al. [4].
The small number of patients with tuberculosis PEs and the dif-
ferent severity grades of disease may explain why our results are
different from previous studies [4, 12, 13].
In all the above reported studies, the number of patients with
tuberculosis PEs was similar to or higher compared with those
with malignant PEs while in our study patients with tuberculosis
PEs (n = 5) were lower than those with PEs of malignant origin
(n = 70). The difference incidence towards neoplastic diseases
compared with benign diseases probably is due to the fact that
ours is a thoracic surgery unit where patients have been referred
for receiving a surgical biopsy and/or treatment.
Mycobacterium tuberculosis is able to induce an extensive in-
flammatory response in the human host, which may reflect a par-
ticular involvement of MMPs in granuloma formation in this
organism. Sheen et al. [4], in fact, observed that tuberculous granu-
loma formation was associated with increased MMP-9 levels in
PEs. Among patients with pleural tuberculosis, MMP-9 concentra-
tions were significantly higher in patients in whom granulomas
were detected on biopsy compared with non-granulomatous
pleural biopsies. In addition, cells adjacent to caseous necrosis in
the granuloma presented high MMP-9 levels, which may be impli-
cated in the process of caseation. Similarly, Park et al. [12]
described that MMP-9 is produced predominantly by epithelioid
cells in the granulomas of tuberculous pleural tissues, whereas lym-
phocytes are the major cellular source of MMP-9 in patients with
malignant effusions. In our study population, only 1/5 patients with
tuberculosis PEs presented with a granuloma on pleural biopsy.
Furthermore, in addition to data published by Iglesias et al. [6],
we also observed a significant difference in MMP-9 and TIMP-1
levels between PEs of benign and of malignant origin. It is well
known that the different extension of pleural involvement by neo-
plastic and infectious disease may be responsible for the different
results. PEs of malignant origin, in fact, may be associated with
several heterogeneous diseases and can occur as the initial pres-
entation of cancer, as a delayed complication in patients with pre-
viously diagnosed malignancies, or as the first manifestation of
cancer recurrence after therapy. In our study population, all neo-
plastic patients presented multiple pleural involvement during
VATS. In addition, 18/70 (26%) patients were affected by meso-
thelioma with an extent pleural involvement. Similarly, among PEs
of benign origin, all patients but one had parapneumonic effu-
sions that required chest drainage and/or VATS debridement.
Thus, the high levels of markers seen in our study may be related
to the extension of pleural involvement whereas lower concentra-
tions of MMP-9 and TIMP-1 would be expected when the pleura
is only recently affected by tumour or infection.
An intriguing finding was the significant correlation between
MMP-9 and TIMP-1 levels. Under normal physiological condi-
tions, TIMP-1 reduces the activity of MMP-9. Thus, the imbal-
ance between MMP-9 and TIMP-1 levels could provide a
favourable biological environment for cancer cell growth and
metastasis [6, 14]. Arnold et al. [15], in a study population of 39
samples, found that all metastatic brain tumours immunohisto-
chemically expressed MMP-9, while 97% of samples were found
to be negative for TIMP-1. Also Gonzales et al. [16] found a high
MMP-9 activity without the increase of TIMP-1 levels in small-cell
lung cancer, as a reflection of its clinical metastatic behaviour.
Thus, since all our neoplastic patients had multiple pleural metas-
tases, we would expect an alteration of balance between MMP-9/
TIMP-1 towards MMP-9. In contrast, we found high TIMP-1 levels
that were significantly correlated with MMP-9 which might sug-
gest a strong response by organism for limiting MMP-9 gelatinoly-
tic activity and, thus, tumour progression. Unfortunately, our data
do not provide evidence for a causal relationship between the
elevated levels of TIMP-1 and MMP-9. The mechanisms related
to the observed correlations remain still unclear and need to be
further investigated.
The evaluation of MMP-9 and TIMP-1 in PE revealed signifi-
cantly higher levels than those observed in serum, but no signifi-
cant correlations were found. These data may be explained by a
possible compartmentalization of these enzymes in the pleural
space, as previously observed by Hurewitz et al. [17]. The pres-
ence of MMP-9 and TIMP-1 in PEs is not simply due to the ultra-
filtration from blood, but several cell types as mesothelial cells,
monocyte/macrophages, lymphocytes, neutrophils and stromal
cells have been reported as a source of MMP-9 and TIMP-1 in
pleural cavity on the basis of underlying disease. Iisaza et al. [10], in
fact, found that the frequency of tumour samples expressingMMP-9
was much lower than that of cases with elevated MMP-9 levels in
plasma. Since macrophages stained positive for MMP-9 in tumour
samples, despite the absence of inflammatory cell infiltrate, it is pos-
sible that macrophages release MMP-9 in the pleural space and are
stimulated by the same tumour cells for producing regulatory
factors, such as cytokines and chemokines. This hypothesis was
also supported by the findings of Hrabec et al. [18]. Park et al. [13]
who identified high rate of lymphocytes in malignant PEs com-
pared with tuberculosis PEs, suggesting that, in neoplastic PEs, lym-
phocytes were the major cellular source of MMP-9.
These results also explained the similar MMP-9 and TIMP-1
levels observed in PEs with positive and negative cytology, since
other cell types, as well as neoplastic cells, are able to release
MMP-9 and TIMP-1 in pleural space.
The ELISA method measures the latent but not the active
MMP-9 form, which is the only one capable of digesting collagen
IV and is involved in metastatic processes. Ondo et al. [14] found
no significant difference between MMP-9 levels, measured by
ELISA, in NSCLC patients and healthy control. However, they
showed that the active form of MMP-9 was an important marker
for the evaluation of cancer progression. Thus, in order to quantify
MMP-9 activity, we used gelatin zymography and we detected in
all neoplastic patients two predominant MMPs isoforms, MMP-9
and MMP-2, which are both type IV collagenases, with different
molecular weights, involved in the degradation of extracellular
matrix. However, MMP-9 presented a higher enzymatic activity than
MMP-2, probably because MMP-2 production seems to be related
to physiological process of transudative PE formation, whereas
MMP-9 is mostly active in exudative PE formation, as previously
reported by Eickelberg et al. [19]. Also Hurewitz et al. [17] found the
presence of MMP-2 and MMP-9 in 32 PEs, but could not correlate
their pattern expression with the origin of pleural disease.
Compared with other tumour markers, MMP-9 and TIMP-1
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sensitivity. Probably, these differences could be a consequence of
a slight difference in tumour origins in the sample of this study
where mesothelioma represents the 26% of PEs and gastrointes-
tinal tumour the 28.5%. Gastrointestinal tumours commonly
present increased levels of CEA, whereas mesotheliomas have
usually low levels of CEA and CA 15.3 [20]. Although the frequency
of increased levels of each tumour marker depends on the
tumour origin, in our analysis the increase of MMP-9 and TIMP-1
level seems not to be organ-specific, since different cancers
showed similar levels.
In clinical practice, the dosage of MMP-9 and TIMP-1 could
improve diagnostic value of pleural fluid analysis, considering that
PEs of neoplastic origin with negative cytology are all diagnosed by
measuring MMP-9 and TIMP-1 levels. In this way, VATS could be
indicated in patients having exudative PEs with MMP-9 and TIMP-l
above the cut-off points while a clinical follow-up could be pre-
ferred in other cases with suspicion of benignity according to clinical
and radiological findings and low levels of MMP-9 and TIMP-1.
The evaluation of several tumour markers, including MMP-9
and TIMP-1, requires higher costs than the simple cytological ana-
lysis of PEs. The cost for measuring MMP-9 or TIMP-1 by ELISA
method, in fact, is about 1.000 Euros for about 40 samples, which
means that the cost for measuring each marker is 25 Euros per
patient. However, the measurement of MMP-9 and TIMP-1 may
avoid the necessity of performing VATS in selected cases econom-
ically, as VATS is a surgical procedure which requires an operative
room with a dedicated staff.
Considering the different results from previous studies [4, 6, 12,
13], before proposing the standard measurements of these
markers in diagnostic work-up of exudative PEs, our data should
be corroborated with future larger studies.
CONCLUSIONS
In differential diagnosis of exudative PEs, the evaluation of MMP-9
and TIMP-1 may represent a rapid, inexpensive, practical and ac-
curate tool for differentiating exudate PEs of benign origin from
those of malignant origin. They presented a high specificity with
cut-off points that offered also a high sensitivity. In addition, our
data suggest that MMP-9 and TIMP-1 levels are not influenced by
the histology and tumour origin neither by the presence of
tumour cells in PEs. Thus, their use in clinical practice could help
in the selection of patients needing more invasive procedures,
such as thoracoscopic biopsy.
Conflict of interest: none declared.
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